Application of TDM, pharmacogenomics and biomarkers for neurological disease pharmacotherapy: Focus on antiepileptic drugs

William Clarke, Gwen McMillin

Research output: Contribution to journalReview articlepeer-review

Abstract

Anticonvulsants, or antiepileptic drugs (AEDs), are a vital tool in the therapeutic management of epilepsy patients. However, many AEDs are commonly used in the management of nonepileptic conditions, such as chronic pain, migraine headaches and psychiatric disorders. It is well documented that serum drug levels are an important data tool for the management of patients taking these drugs. As we move toward the personalized optimization of pharmacotherapy, drug level data will not be sufficient. This article will review tools for therapeutic drug management of AEDs including pharmacogenetics and biomarkers, in addition to traditional serum drug levels.

Original languageEnglish (US)
Pages (from-to)139-149
Number of pages11
JournalPersonalized Medicine
Volume3
Issue number2
DOIs
StatePublished - May 1 2006

Keywords

  • Antiepileptic drugs
  • Biomarkers
  • Bipolar disorder
  • Chronic pain management
  • Epilepsy
  • Migraine
  • Pharmacogenetics
  • Therapeutic drug management

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Application of TDM, pharmacogenomics and biomarkers for neurological disease pharmacotherapy: Focus on antiepileptic drugs'. Together they form a unique fingerprint.

Cite this